Pazopanib (DrugBank: Pazopanib)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 227 | Osler disease | 2 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03850730 (ClinicalTrials.gov) | September 2019 | 12/2/2019 | Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia | An Open-label, Non-randomized Study of the Efficacy of Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) | Hereditary Hemorrhagic Telangiectasia;Epistaxis | Drug: Pazopanib | Cure HHT | University of North Carolina | Not yet recruiting | 18 Years | 75 Years | All | 30 | Phase 1;Phase 2 | NULL |
| 2 | NCT03850964 (ClinicalTrials.gov) | September 2019 | 12/2/2019 | Pazopanib Effects on Bleeding in Hereditary Hemorrhagic Telangiectasia | Randomized Double Blind Study to Evaluate the Effect of Low Dose Pazopanib on Bleeding Due to Hereditary Hemorrhagic Telangiectasia | Hereditary Hemorrhagic Telangiectasia;Epistaxis Nosebleed;Anemia | Drug: Pazopanib;Drug: Placebo oral capsule | Cure HHT | NULL | Not yet recruiting | 18 Years | 75 Years | All | 45 | Phase 2;Phase 3 | NULL |